Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved two new complement C5-targeting therapies for adults with AChR-antibody-positive generalized myasthenia gravis (gMG) within days of each other. Gefurulimab (Klygefa) offers once-weekly self-administered subcutaneous dosing, while cemdisiran (Livsayis) — the first approved siRNA therapy for gMG — requires only four injections per year. Together, they bring the total complement-targeted options for gMG to four, giving clinicians and patients more flexibility than ever before.
The FDA has approved two new complement C5-targeting therapies for adults with AChR-antibody-positive generalized myasthenia gravis (gMG) in quick succession, significantly expanding the treatment landscape for a disease that affects an estimated 85,000–98,500 Americans.
First, gefurulimab (Klygefa; Alexion/AstraZeneca) — the first dual-binding nanobody C5 inhibitor — was approved for once-weekly self-administered subcutaneous injection. Its concurrent binding to serum albumin extends its half-life, enabling at-home dosing via autoinjector. Days later, cemdisiran (Livsayis; Regeneron) became the first approved siRNA therapy for gMG, working upstream by silencing hepatic C5 production rather than binding circulating C5 protein — and requiring only four subcutaneous injections per year.
Both approvals were supported by robust phase 3 data: gefurulimab from the PREVAIL trial and cemdisiran from the NIMBLE trial, each demonstrating statistically significant and clinically meaningful improvements in MG-ADL and QMG scores versus placebo. Both carry boxed warnings for serious meningococcal infections and require REMS enrollment with pre-dose vaccination.
By the Numbers:
Why it matters: With four complement-targeted therapies now approved for gMG, clinicians have meaningful options to tailor treatment to patient lifestyle, disease severity, and dosing preferences — a major shift from the era of broad immunosuppression alone.